Hydropyridine derivative acid addition salts, process of their preparation and use
Abstract
Acid addition salts of 2-acetoxy-5-( alpha -cyclopropyl-carbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothienoÄ3,2-cÜ- pyridine. ÄEffectsÜ The acid addition salts of tetrahydrothienopyridine derivatives of the present invention exhibit excellent oral absorption, metabolisation into the active compound, and platelet aggregation-inhibiting effects, low toxicity, and excellent storage and handling stabilities, and are useful as medicaments, preferably preventive or therapeutic agents (particularly therapeutic agents) for diseases caused by thrombus or embolus, still more preferably preventive or therapeutic agents (particularly therapuetic agents) for thrombosis or embolism.

Term
Term ended
Projected expiry passed 3 July 2021, 5.2 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
22 claims: 11 independent, 11 dependent
- 1PATENTOVÉ NÁROKY 1. Adiční sůl 2-acetoxy-5-cc-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7.-tetrahydrothieno[3,2-c]pyridinu s kyselinou.
- 2Adiční sůl 2-acetoxy-5-a-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinu, vyznačuj ící se tím, že sůl je hydrochlorid nebo maleinát.
- 32-Acetoxy-5-a-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothieno[3,2- c]pyridin hydrochlorid.
- 42-Acetoxy-5 -a-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothieno [3,2•cjpyridin maleinát.
- 5Léčivo, vyznačující se tím, že obsahuje jako účinnou složku sůl podle kteréhokoliv z nároků 1 až 4.
- 6Léčivo podle nároku 5, vy značuj í cí se t ím , že je určeno pro prevenci nebo léčbu onemocnění související s tvorbou trombů nebo embolií u teplokrevných živočichů.
- 7Léčivo podle nároku 5, vyznačuj ící se tím, že je určeno pro léčbu nebo ------prevenci trombózy a embolie u člověka.----------- - - ------------- · ...........—
- 8Léčivo podle nároku 5, v y z n a č u j í c í se tím, že je určeno pro léčbu trombózy a embolie u člověka.
- 9Způsob léčby nebo prevence onemocnění souvisejícího s tvorbou trombů nebo embolií u teplokrevných živočichů, vyznačující se tím, že zahrnuje podání účinného množství soli podle kteréhokoliv z nároků 1 až 4.
- 10Způsob prevence nebo léčby trombózy nebo embolie u člověka, vyznačující se t í m, že zahrnuje podání účinného množství soli podle kteréhokoliv z nároků 1 až 4.
- 11Způsob léčby trombózy nebo embolie u člověka, vyznačující se tím, že zahrnuje podání účinného množství soli podle kteréhokoliv z nároků 1 až 4.
- 12Způsob přípravy adiční soli 2-acetoxy-5-a-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7~ tetrahydrothieno [3,2-c]pyridinu s kyselinou, vyznačující se tím, že zahrnuje přidání 2-acetoxy-5-a-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothieno[3,2/Lí.......- 20 - cjpyridinu do roztoku kyseliny v inertním rozpouštědle a pokud je to nezbytné následné přidání krystalizačních oček.
- 13Způsob přípravy adiční soli s kyselinou podle nároku 12, vyznačující se tím, že inertní rozpouštědlo je aceton a kyselina je kyselina maleinová.
- 14Způsob přípravy adiční soli 2-acetoxy-5-a-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinu skyselinou, vyznačující se tím, že zahrnuje přikapání kyseliny, jedno nebo opakované, do roztoku 2-acetoxy-5-a'CykIopropylkarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinu v inertním rozpouštědle a pokud je to nezbytné následné přidání krystalizačních oček.
- 15Způsob přípravy adiční soli s kyselinou podle nároku 14, v y z n a č u j í c í se tím, že inertní rozpouštědlo je aceton a kyselina je koncentrovaná kyselina chlorovodíková.
- 16Způsob přípravy 2-acetoxy-5-a-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothieno[3,2-c]pyridin hydrochloridu, vyznačující se tím, že zahrnuje přikapání poloviny z požadovaného množství koncentrované kyseliny do roztoku 2- acetoxy-5-a-cyklopropylkarbonyl-2-fluorbenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridinu v inertním rozpouštědle, pokud je to nezbytné následné přidání krystalizačních oček, přikapání dalšího množství koncentrované kyseliny chlorovodíkové při stejné teplotě a následná reakce.při stejné teplotě.______________________ ____________________________ _____________________
- 17Způsob přípravy hydrochloridu podle nároku 16, vyznačující se tím, že zvýšená reakční teplota je v rozmezí 35 až 60 °C.
- 18Způsob přípravy hydrochloridu podle nároku 16, vyznačující se tím, že zvýšená reakční teplota je v rozmezí 40 až 55 °C.
- 19Způsob přípravy hydrochloridu podle nároků 16 až 18, vy zn a č uj í c í se tím, že doba přikapávání poloviny požadovaného množství koncentrované kyseliny chlorovodíkové je v rozmezí 2 až 10 min.
- 20Způsob přípravy hydrochloridu podle nároků 16 až 19, v y zn a č uj í c í se tím, že doba přikapávání poloviny požadovaného množství koncentrované kyseliny chlorovodíkové jev rozmezí 30 min až 2 h.
- 21Způsob přípravy hydrochloridu podle nároků 16až 20, vyznačující se tím, že doba přikapávání zbytku požadovaného množství koncentrované kyseliny chlorovodíkové je v rozmezí 15 min až 2 h.
- 22Způsob přípravy hydrochloridu podle nároků 16 až 21,-v y z n a č uj í c í se tím, že doba přikapávání zbytku požadovaného množství koncentrované kyseliny chlorovodíkové je v rozmezí 1 až 3 h.
Independent claims22
164 paragraphs in 3 sections, as filed
Technical field
The present invention relates to acid addition salts of 2-acetoxy-5- (α-cyclopropyl-carbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine (preferably hydrochloride or maleate) which they exhibit exceptional oral absorption, metabolic conversion to active ingredient, and effective inhibition of platelet aggregation, and are useful therapeutics or prophylactics in diseases induced by thrombus or embolism.
BACKGROUND OF THE INVENTION
EP-542411 (Japanese Patent Application No. Hei 6,411,239) discloses that
2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine and its derivatives, as adenosine diphosphate (ADP) receptor antagonists, exceptionally inhibit blood clumping and are useful as antithrombotics or antiembolics.
SUMMARY OF THE INVENTION
For many years the pharmacological effects of various hydropyridine derivatives have been studied and an exceptional platelet aggregation inhibitor has been sought. It has been found that acid addition salts of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine, preferably hydrochloride or maleate, show excellent oral absorption, are metabolized to the active substance, effectively inhibit platelet aggregation, have low toxicity, they are stable in storage and processing and are therefore excellent drugs (preferably therapeutics and prophylactics (preferably therapeutics)) in diseases induced by the formation of thrombi or embolism (preferably thrombosis or embolism).
<td></td><td> • ·</td><td> • · · ·</td><td> • 4 · 4 4 4</td>
<td></td><td> •</td><td> 4 4 ·</td><td> 4 · ·</td>
<td></td><td> •</td><td> • · 4 • · · · · ·</td><td> • · 4 4 4 4 4 4</td>
The present invention provides 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine acid addition salts, preferably hydrochloride or maleate, which effectively inhibit aggregation platelets; methods for their preparation; and medicaments comprising, useful in the treatment and prophylaxis (preferably treatment) of diseases induced by the formation of thrombi or embolism, and preferably useful in the treatment and prophylaxis (preferably treatment) of thrombosis or embolism.
The present invention relates to an acid addition salt of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine, preferably hydrochloride or maleate, and medicaments containing acid addition salts of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine as active ingredient.
A suitable acid component of the 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine addition salt is, for example, an inorganic acid such as sulfuric acid, hydrochloric acid, nitric acid , phosphoric; or organic acids such as trifluoroacetic, maleic, methanesulfonic, p-toluenesulfonic, and preferably hydrochloric or maleic.
The 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride of the present invention is a compound of the structural formula
<img file="CZ20030018A3_D0001.tif" />
<img file="CZ20030018A3_D0002.tif" />
2-Acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine maleate is a compound of the structural formula
<img file="CZ20030018A3_D0003.tif" />
.COOH í
ΌΟΟΗ
The acid addition salt of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine contains an asymmetric carbon and therefore each compound is present in two diastereomeric forms o R or S configuration. The present invention includes both individual isomers and mixtures thereof. The optically active isomer of the 2acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydro-thieno [3,2-c] pyridine acid addition salt of the present invention can be prepared from the optically active starting material, or its can be isolated from the racemic mixture of the synthetically prepared 2-acetoxy-5- (acyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine acid addition salt with a conventional separation procedure for optically pure materials.
In some cases, when crystallizing the 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine addition salt with an acid, the crystallization solution contacts the atmospheric solution Moisture may form. The present invention also encompasses this type of hydrate.
Acid addition salts of 2-acetoxy-5- (α, -cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine are prepared in the presence or absence of an inert solvent by addition of 2-acetoxy -5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine, prepared according to the procedure described in EP-542411 (Japanese patent application Hei 6-41139) to an acid (preferably hydrochloric, hydrogen chloride gas, maleic; more preferably concentrated hydrochloric or maleic acid; most preferably, concentrated hydrochloric acid); in the presence or absence of an inert solvent (preferably ih in the presence of an inert solvent) by dropwise addition or addition of an acid (preferably hydrochloric acid, hydrogen chloride gas or maleic acid; more preferably concentrated hydrochloric acid or maleic acid; most preferably concentrated hydrochloric acid) all at once or in portions of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine. This process includes, if desired, adding crystallization seeds to the reaction mixture.
The choice of inert solvent as described above is not limited, provided that it has no adverse effect on the reaction and that it dissolves the starting reagents at least to some extent. Examples of suitable solvents are: aliphatic hydrocarbons such as hexane, cyclohexane, heptane, ligroin or petroleum ether; aromatic hydrocarbons such as benzene, toluene or xylene; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, chlorobenzene or dichlorobenzene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane or di (ethylene glycol) dimethyl ether; ketones such as acetone, methyl ethyl ketone or diethyl ketone; esters such as ethyl acetate, propyl acetate or butyl acetate; carboxylic acids such as acetic or propionic acid; nitriles such as acetonitrile or propionitrile. The hydrochlorides are preferably prepared in solvents such as ethers, ketones, esters, carboxylic acids or nitriles, more preferably tetrahydrofuran, dioxane, acetone, methyl ethyl ketone, ethyl acetate, acetic acid or acetonitrile; even more preferably tetrahydrofuran, dioxane, acetic acid or acetone. The most preferred solvent is acetone. The maleate is preferably prepared in solvents such as ethers, ketones, esters or nitriles, more preferably tetrahydrofuran, dioxane, acetone, methyl ethyl ketone, ethyl acetate or acetonitrile; more preferably tetrahydrofuran, dioxane or acetone. The most preferred solvent is acetone.
The reaction temperature is controlled by the solvent and the like used, usually in the range of -20 to 100 ° C, preferably 0 to 70 ° C. For the preparation of the hydrochloride, the reaction temperature is preferably 30 to 60 ° C, more preferably 40 to 55 ° C.
The reaction time depends on the type of reagents, solvent, reaction temperature and the like, usually in the range of 5 min to 10 h.
In the preparation of maleates, the reaction is preferably carried out by adding 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine to a solution of maleic acid in acetone at 0 to 70 ° C and the reaction is allowed to stand at an initial temperature of 1 to 3 h.
<img file="CZ20030018A3_D0004.tif" />
In the preparation of hydrochlorides, the reaction is preferably carried out by dropwise addition of the desired amount of concentrated hydrochloric acid (usually equimolar to the thienopyridinic acid derivative) to a solution of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) 4,5,6,7-tetrahydrothieno [3] 2-c] pyridine in acetone at 0 to 70 ° C (preferably 35 to 60 ° C) and the reaction is allowed to stand at the starting temperature for 30 min to 3 h.
Even more preferably, the reaction is carried out by dropwise adding half of the desired amount of concentrated hydrochloric acid (usually equimolar to the thienopyridine derivative) to a solution of the thienopyridine derivative in acetone at 35 to 60 ° C (preferably 40 to 55 ° C) over 2 to 10 min. adding crystallization seeds of the desired salt, if necessary, and allowing the reaction mixture to stand for 30 min to 2 h; in addition, the remainder of the desired amount of concentrated hydrochloric acid is added dropwise over 30 min to 2 h and the reaction mixture is allowed to stand at the reaction temperature for 1 to 3 h.
After the reaction, the resulting 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine salt is isolated from the reaction mixture by conventional means. For example, the formed crystals may be filtered off or the solvent evaporated. If necessary, the product can be purified by repeated crystallization, precipitation or chromatography.
The present-addition salts of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine exhibit excellent oral absorption, metabolic conversion to the active ingredient, inhibition of blood clotting platelets, low toxicity, excellent storage and handling stability; therefore, they are useful for the prophylaxis or therapy (preferably therapy) of diseases associated with thrombus formation or embolism; more preferably in the prophylaxis or treatment (more preferably, treatment) of thrombosis or embolism. The medicaments described above are for warm-blooded animals, more preferably for humans.
The present 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine addition salts used as prophylactics or therapeutics for the above-mentioned diseases are administered alone or in admixture with acceptable excipients, diluents, in various dosage forms such as tablets, capsules, granules, powders, syrups and the like.
for oral administration; in the form of injections, suppositories, etc. for parenteral administration.
• · ···
Each of the above compositions can be prepared by known techniques using additives such as excipients, lubricants, binders, disintegrants, emulsifiers, stabilizers, corrective additives and diluents.
Examples of excipients include organic excipients, eg, sugar derivatives such as lactose, sucrose, glucose, mannitol or sorbitol; starches such as cereal starch, potato starch, α-starch or dextrin; celluloses such as crystalline cellulose; acacia; dextran; pullulan; inorganic excipients such as e.g. silicate derivatives such as light silicic anhydride, synthetic aluminosilicate, calcium silicate, magnesium aluminum metasilicate; phosphates such as dibasic calcium phosphate; carbonates such as calcium carbonate; sulfates such as calcium sulfate and the like;
Examples of lubricants include stearic acid, stearic acid salts such as calcium or magnesium; talc, waxes such as beeswax or spermacet; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fumaric acid; sodium benzoate; DL-leucine; salts of lauryl sulfate such as sodium or magnesium; silicic acid derivatives such as anhydride or hydrate; and starches listed above.
Examples of binders include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol (trade name) or excipients detailed above.
Examples of disintegrants include cellulose derivatives such as low-substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium, or internally cross-linked sodium carboxymethylcellulose; chemically modified starch or cellulose derivatives such as carboxymethyl starch or its sodium salt; cross-linked polyvinylpyrrolidone and starch derivatives described above.
Examples of emulsifiers include colloidal clays such as bentonite or veegum; metal hydroxides such as magnesium or aluminum hydroxide; anionic surfactants such as sodium lauryl sulfate or calcium stearate; cationic surfactants such as benzalkonium chloride; nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid esters or fatty acid esters of sucrose.
Examples of stabilizers include para-hydroxybenzoic acid esters such as methylparaben; alcohol derivatives such as chlorobutanol, benzyl alcohol or phenethyl alcohol; benzalkonium chloride; phenol derivatives such as phenol or cresol; thimerosal, dehydroacetic acid or sorbic acid. 1
<img file="CZ20030018A3_D0005.tif" />
Examples of corrective ingredients include sweeteners, flavors, flavorings and other commonly used ingredients.
The specific dose of the present compound is governed by the severity of the disease symptoms, the age of the patient and the like. For oral administration, the amount of active ingredient is in the range of 0.1 to 1000 mg, preferably 1 to 500 mg. The dosage amount of the present compound for intravenous injection is in the range of 0.001 to 500 mg, preferably 0.1 to 250 mg.
The dosage unit may be administered to an adult patient 1 to 7 times daily for 1 to 7 days depending on the severity of the disease symptoms.
In the following, the invention is explained in more detail by way of examples, which, however, are provided by way of illustration only and are not intended to limit the invention in any way.
DETAILED DESCRIPTION OF THE INVENTION
Example 1
2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride (crystal A)
To a solution of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine (10 g), prepared according to Reference Example 1, in acetone (150 g). ml) was added dropwise 36% hydrochloric acid (2.71 g) with stirring at room temperature (25 ° C). To the solution was added a small amount of crystals of the desired product (crystals A, prepared by another process) as crystallization centers, and the mixture was stirred at the same temperature for 90 min. The resulting crystals were filtered off, washed with a small amount of acetone and dried for 4h at 50 ° C under reduced pressure to yield 8.1 g; 74 wt. crystals A of the title compound.
mp: 133-136 ° C 1 H NMR (CDCl 3)?<sub>3</sub>; δ ppm): 0.92-0.99 (1H, m), 1.05-1.16 (2H, m), 1.23-1.34 (1H, m), 1.84-1.95 (1H, m), 2.26 (3H, s), 3.07-3.23 (2H, m), 3.57-4.39 (4H, m), 6.04 (1H, s), 6.45 (1H, brs), 7.37-7.57 (3H, m), 7.66-7.75 (1H, m);
MS (CI, m / z): 374 (MH +)<sup>+</sup>+ 1);
IR (KBr, para<sub>max</sub> cm '<sup>1</sup>: 1762,1720.
Example 2
2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine maleate
To a solution of maleic acid (4.43 g) in acetone (60 mL) was added 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2- c] pyridine (15 g), prepared according to Reference Example 1, the reaction mixture was stirred at room temperature (25 ° C) for 2 h. The formed crystals were filtered off, washed with a small amount of acetone and dried for 4 h at 50 ° C under reduced pressure. yield 17.1 g; 92 wt. of the title compound.
mp: 171-172 ° C 1 H NMR (CDCl 3)?<sub>3</sub> FROM; δ ppm): 0.89-0.97 (1H, m), 1.02-1.09 (2H, m), 1.14-1.23 (1H, m),
1.94-2.03 (1H, m), 2.25 (3H, s), 3.00-3.09 (2H, m), 3.33-3.50 (2H, m), 3, 88 (1H, d, J = 14.9Hz), 4.05 (1H, d, J = 14.9Hz), 5.70 (1H, s), 6.25 (2H, s), 6, 40 (1H, s), 7.30-7.42 (2H, m), 7.45-7.52 (1H, m), 7.56-7.66 (1H, m);
MS (CI, m / z): 374 (MH +)<sup>+</sup>+1);
IR (KBr, para<sub>max</sub> cm '<sup>1</sup>: 1782, 1713.
Example 3
2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride (crystal Β1)
To a solution of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine (10 g), prepared according to Reference Example 1, in acetone ( 100 ml) was added dropwise 36% hydrochloric acid (2.71 g) with stirring over 1 min at 40 ° C. The reaction mixture was then stirred at 40 ° C for a further 60 min (crystals began to appear ten minutes after acidification of the reaction mixture). The formed crystals were filtered off, washed with acetone (20 ml) and dried for 2 h at 60 ° C under reduced pressure to yield 9.72 g; 89 wt. crystals B1 having better storage stability than crystals A.
<img file="CZ20030018A3_D0006.tif" />
Example 4
2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride (crystal B2)
To a solution of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine (50 g), prepared according to Reference Example 1, in acetone (750 ml) was added dropwise 36% hydrochloric acid (6.78 g) with stirring over 5 min at 40 ° C. Crystals B2 (0.1 g) prepared in Example 3 were added to the mixture as crystallization centers and the mixture was stirred at the same temperature for 60 min. Concentrated acid was then added dropwise to the resulting mixture. hydrochloric acid (36%, 6.10 g) over 60 min and the mixture was stirred at the same temperature for 120 min. The resulting crystals were filtered, washed with acetone (100 mL) and dried at 70 ° C for 3 h under reduced pressure to yield 47.8 g; 92 wt. white crystals B2 having better storage stability than crystals B1.
Example 5
2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine maleate
To a solution of maleic acid (932 g) in acetone (151) heated to 40 ° C was added 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno- [3,2] -c] pyridine (3000 g), prepared according to Reference Example 1. The reaction mixture was stirred at room temperature (25 ° C) for 2 h. The formed crystals were filtered, washed with acetone (41) and dried for 8 h at 60 ° C under reduced pressure. pressure, yield 3538 g; 90 wt. white crystals of the title compound.
Example 6
2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride (crystal B2)
To a solution of 2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine (50 g), prepared according to Reference Example 1, in acetone (750 ml) was added dropwise 36% hydrochloric acid (6.78 g) with stirring over 5 min at
<img file="CZ20030018A3_D0007.tif" />
temperature 55 ° C. Crystals B1 (0.1 g) prepared in Example 3 were added to the mixture as crystallization centers and the mixture was stirred at the same temperature for 60 min. To the resulting mixture was further added dropwise concentrated hydrochloric acid (36%, 6.08 g) over 60 min, and the mixture was stirred at the same temperature for 120 min. The formed crystals were filtered, washed with acetone (100 mL) and dried at 70 ° C for 3 h under reduced pressure to yield 46.2 g; 89 wt. of B2 crystals.
Reference Example 1
2-acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine (a) Cyclopropyl 2-fluorobenzyl ketone
To a suspension of powdered magnesium (7.2 g) in anhydrous diethyl ether (60 mL) was added a solution of 2-fluorobenzyl bromide (30 mL) in diethyl ether (30 mL), then the mixture was stirred at room temperature for 1 h. to a solution of cyclopropyl cyanide (18.2 mL) in diethyl ether (120 mL) over 100 min. After further stirring for 30 min. at room temperature, the mixture was heated to reflux. After completion of the reaction, the reaction mixture was partitioned between ethyl acetate and saturated ammonium chloride solution. The organic phase was washed successively with water, saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography with toluene to yield 23 g of the desired product (containing solvent) as a yellow liquid.
(b) 5- (α-Cyclopropylcarbonyl-2-fluorobenzyl) -2-oxo-2,4,5,6,7,7a-hexahydrothieno [3,2-c] pyridine
To a solution of cyclopropyl 2-fluorobenzyl ketone (8.7 g) prepared according to Reference Example 1 (a) in carbon tetrachloride (80 mL) was added N-bromosuccinimide (9.6 g) and benzoyl peroxide (0.5 g), mixture The mixture was heated at reflux for 6 h. After completion of the reaction, toluene was added to the mixture and the resulting precipitate was filtered off. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography with toluene as eluent to give acyclopropylcarbonyl-2-fluorobenzyl bromide (8.5 g) as a yellow oil.
·· ···· • · · · · · · · ··· · · · · · • · · · ····
To a solution of α-cyclopropylcarbonyl-2-fluorobenzyl bromide (6 g), prepared as described above, in dimethylformamide (20 mL) was added 2-oxo-2,4,5,6,7,7-hexahydrothieno [3,2-c] ] pyridine hydrochloride (4.8 g), prepared according to the procedure disclosed in EP 192535 (Japanese Patent Application No. Sho 61-246186), and potassium bicarbonate (7.0 g). The mixture was stirred at room temperature for 2 h and the reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with a saturated aqueous sodium chloride solution, dried over magnesium sulfate and evaporated under reduced pressure. After purification by column chromatography on silica gel, eluting with toluene-ethyl acetate = 3/1, the product was crystallized from diisopropyl ether in a yield (2.6 g, 35%) as brownish crystals.
(c) 2-Acetoxy-5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine
To a solution of 5- (α-cyclopropylcarbonyl-2-fluorobenzyl) -2-oxo-2,4,5,6,7,7a-hexahydrothieno [3,2-c] pyridine (2.6 g) prepared according to Reference Example 1 (b) in a mixture of dimethylformamide (10 ml) and acetic anhydride (5 ml) cooled in an ice bath, sodium hydride (60% dispersion in mineral oil (0.3 5 g)) was added and the mixture was stirred under cooling 30 min and an additional 3 h at room temperature. After completion of the reaction, the mixture was extracted with ethyl acetate, and the extract was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified on a silica gel column eluting with toluene-ethyl acetate = 3/1, the product crystallized from diisopropyl ether to yield 1.88 g (65%) of the title compound as white crystals.
Test Example 1
Plasma metabolite concentration in dogs
Plasma metabolite concentrations were determined in male Beagle dogs (about 10 kg, by Kasho Co., Ltd. and (Nippon Nosan Kogyo KK) after oral administration of the test compound using (2Z) - [1-] acid as reference. [-α-cyclopropylcarbonyl-2-fluorobenzyl] -4-methylthio-3-piperidinylidene] acetic acid (hereinafter referred to as "S-methyl form").
S-methyl form is the major metabolite of 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,712
<img file="CZ20030018A3_D0008.tif" />
tetrahydrothieno [3,2-c] pyridine in human, dog or rat plasma. As described, the S-methyl form is a measure of the amount of the active metabolite 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine as it is produced by further downstream metabolism active metabolite [Annu. Rep. Sankyo Res. Lab., 51, 1 (1999)].
Thirty minutes after feeding the dogs with feed, each test compound was administered to the dogs in the form of a gelatin capsule. A blood sample (3 ml) was collected from the brachial vein on the foot by a heparin injection needle at time intervals of 15, 30, 45, 60, 90 and 120 min after administration of the test substance. Immediately after collection, the blood sample was centrifuged to separate the plasma. Plasma samples were stored at -30 ° C until analysis. To 0.5 ml of thawed plasma was added hydroxyacetophenone (0.25 ml) (1 µg / ml as internal standard), 10 mol.l ·<sup>1</sup> potassium phosphate (pH = 4.5) and methanol (0.5 mL). The mixture was stirred at 20 + 3 ° C.
After addition of isopropanol / chloroform (1/9, 8 mL), the mixture was stirred and the S-methyl form and internal standard extracted into the organic phase. The phases were separated by a low speed centrifuge (1500 xg, 15 min). An aliquot was taken from the organic phase, dried with nitrogen and dissolved in 0.25 ml of mobile phase HPLC. A known amount of Smethylform was separately dissolved to the control canine plasma and the same extraction was performed. A calibration curve was plotted by plotting the ratio of the peak area of the S-methyl form on the Y axis and the concentration of added Smethyl form on the X axis. The concentration of the S-methyl form in the sample was calculated from the calibration
HPLC conditions:
Column: YMC A302 (4.6 x 150 mm)
Mobile phase: acetonitrile / isopropanol / water / trifluoroacetic acid (10/12/78 / 0.01) Flow rate: 1.0 ml / min
UV detection 220 nm
Injection: 30 μΐ
The results are shown in Table 1. In this table, the area under the plasma concentration - time curve, the measure of the amount produced in vivo, and the maximum plasma concentration, which are pharmacokinetic parameters, referred to as AUC and Cmax. In this table, the term "hydrochloride" means 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) 4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride prepared in Example 1, while "free" · * ··
<img file="CZ20030018A3_D0009.tif" />
form 'means 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine.
Table 1
Pharmacokinetic parameters (mean + standard deviation) of the S-methyl form in the plasma of dogs after oral administration
<td>Test compound</td><td>n</td><td>AUC (pg.min / ml)</td><td>Cmax (pg / ml</td>
<td>Hydrochloride</td><td> 4</td><td> 74,1 + 25,8</td><td> 1,09 + 0,26</td>
<td>Free form</td><td> 3</td><td> 36,4 + 8,2</td><td> 0,615 ±0,141</td>
<td>The results suggest</td><td>that AUC values</td><td>i Cmax are for</td><td>2-acetoxy-5-a- form</td>
cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride higher.
Test Example 2
Inhibitory effect on platelet aggregation (feeding)
This test was performed on male Beagle dogs (weighing about 10 kg, by Kasho Co., Ltd______ and Nippon Nosan Kogyo KK). One group consisted of five or six dogs. Platelet aggregation was measured on an automatic aggregometer ("PAM-6C", trade name; Mebanix Corporation) according to the procedure of Boma, et al. (J.Physiol., 168, 178 (1963)), slightly modified.
Every 2.5 and 4.5 hours after feeding, dogs were sampled from a blood vein (5.4 ml), using sodium citrate as an anticoagulant (0.6 ml, 3.8% (w / v)). citrate was centrifuged (240 g, 20 min) to separate platelet-enriched plasma (referred to as PRP) and platelet-depleted plasma (PPP). Platelet count ("K-1000", trade name; Sysmex Corporation) was determined in the PRP on an automatic hematology analyzer, and PPP was added to a final concentration of 3 χ 10<sup>8</sup> / ml. The PRP (240 μϊ) was placed in a cuvette and stored in an automatic aggregometer. After preheating (to 37 ° C) for 1 min, 10 μϊ of ADP (final concentration: 20 μιηοΙ.Γ) was added.<sup>1</sup>) to cause platelet aggregation. Clustering was measured for 10 min and the maximum was used as the value before administration of the test compound.
· · · Β β β β β β β β β β β β β β β β β φ φ φ φ β β φ φ φ · ······· · · · · ·.
The next day, 30 min after feeding, the dogs were dosed orally in gelatin capsules. Blood samples were taken 2 and 4 hours after administration. The maximum level of clustering in PRP was determined. Inhibition (%) of clustering by test compounds was calculated by comparison with the value measured prior to compound administration. The results are shown in Tables 2 and 3.
In these tables, the term "hydrochloride" means 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride prepared in Example 1, while "free form" "Means 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine and" maleate "means 2-acetoxy-5-α-cyclopropylcarbonyl-2 • fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine maleate prepared in Example 2.
Table 2
Inhibition of platelet aggregation (mean + standard deviation) after oral administration in dogs.
<td rowspan="2">Test compound</td><td rowspan="2">Dose (mg / kg)</td><td rowspan="2">n</td><td>Inhibition (%) of clustering</td>
<td>2h 4h</td>
<td>Hydrochloride</td><td> 0,3</td><td> 5</td><td> . 49,0 ± 18,7 48,5 ± 18,3</td>
<td>Free form -----------------'—</td><td></td><td> -5 -</td><td> 25,8 ± 10,9-------------28,6 ± 14,2---------</td>
Table 3
Inhibition of platelet aggregation (mean + standard deviation) after oral administration in dogs.
<td rowspan="2">Test compound</td><td rowspan="2">Dose (mg / kg)</td><td rowspan="2">n</td><td colspan="2">Inhibition (%) of clustering</td>
<td>2h</td><td>4h</td>
<td>Maleinate</td><td> 0,3</td><td> 5</td><td> 50,9 ±14,5</td><td> 58,6 ± 15,7</td>
<td>Free form</td><td> 0,3</td><td> 5</td><td> 21,7 + 9,8</td><td> 23,8 ± 12,6</td>
<91 v v v v v 91 v v v v v 91 91 91 91 91 91 91 91 91 v 91 91 91 91 91 91 91 · ···············
Test Example 3
Inhibitory effect on platelet aggregation (fasting)
This test was performed on male Beagle dogs (weighing about 10 kg, by Kasho Co., Ltd. and Nippon Nosan Kogyo KK). One group consisted of three dogs. Platelet aggregation was measured on an automatic aggregometer ("PAM-6C", trade name; Mebanix Corporation) according to the procedure of Boma, et al. (J.Physiol., 168, 1978 (1963)), slightly modified.
After fasting overnight, dogs were sampled from a cephalic vein (5.4 ml) using sodium citrate as an anticoagulant (0.6 ml, 3.8% (w / v). Citrate blood was centrifuged (240 ml). g, 20 min) to separate platelet-enriched plasma (referred to as PRP) and platelet-depleted plasma (PPP) The platelet count ("K-1000", trade name; Sysmex Corporation) was determined in the PRP on an automatic hematology analyzer. ), o
and PPP was added to a final concentration of 3 x 10 / ml. The PRP (240 μΐ) was placed in a cuvette and stored in an automatic aggregometer. After preheating (to 37 ° C) for 1 min, 10 μΐ of ADP (final concentration: 20 μιηοΙ.Γ) was added.<sup>1</sup>) to cause platelet aggregation. Clustering was measured for 10 min and the maximum was used as the value before administration of the test compound.
The next day, dogs were administered test compounds orally, in the form of gelatin capsules. Blood samples were taken 2 and 4 hours after administration. The maximum level of clustering in PRP was determined. Inhibition (%) of clustering by test compounds was calculated by comparison with the value measured prior to compound administration. The results are shown in Table 4.
In this table, the term "maleate" means 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine maleate prepared in Example 2, while "free form" Means 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine.
Table 4
Inhibition of platelet aggregation (mean + standard deviation) after oral administration in dogs.
Test Compound Dose n Inhibition (%) clumping (mg / kg)
2h
4h * e to to to to to a a a a a a a a a a a toto toto toto toto toto toto toto toto toto toto toto
Maleinate
1,0
63,4 + 22,9
88,5 + 5,7
Free form
1,0
27,9 ± 24,8
28,7 + 24,4
Test results 2 and 3 suggest that the inhibitory effect of 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride and maleate on ADP-induced platelet aggregation is stronger than that of the free form 2-acetoxy-5-acyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine and 2-acetoxy-5-acyclopropylcarbonyl-2-fluorobenzyl) -4,5,6, 7-tetrahydrothieno [3,2-c] pyridine hydrochloride and maleate both exhibit better pharmacological effects than 2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine.
Example of preparation of dosage form 1
Hard capsules'
2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride in powder form (50 mg), lactose (128.7 mg), cellulose (70 mg) and magnesium stearate (1.3 mg) were mixed, sieved (60 mesh) and filled into hard gelatin capsules (# 3, 250 mg).
Example of preparation of dosage form 2
Tablet
2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride in powder form (50 mg), lactose (124 mg), cellulose (25 mg) and magnesium stearate (1 mg) are mixed and compressed on a tabletting machine into 200 mg tablets, which can be coated if desired.
Preparation Example 3 Hard Capsule
<img file="CZ20030018A3_D0010.tif" />
<img file="CZ20030018A3_D0011.tif" />
2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine maleate powder (50 mg), lactose (128.7 mg), cellulose (70 mg) and magnesium stearate (1.3 mg) was mixed, sieved (60 mesh) and filled into hard gelatin capsules (No. 3, 250 mg).
Preparation Example 4
Tablet
2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine maleate powder (50 mg), lactose (124 mg), cellulose (25 mg) and magnesium stearate (1 mg) are mixed and compressed on a tabletting machine into 200 mg tablets, which can be coated if desired.
4 'fc ..
KS '.
Industrial applicability
2-acetoxy-5-α-cyclopropylcarbonyl-2-fluorobenzyl) -4,5,6,7-tetrahydrothieno [3,2-c] pyridine hydrochloride and maleate are pharmaceutically useful platelet aggregation inhibiting agents.
·· · · · · ·· ····
Contents3
11 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11
69 members in 26 offices
Priority claims8
| Document | Office | Kind | Date |
|---|---|---|---|
| 2000205396 | Japan | A | |
| 2000205396 | Japan | A | |
| 2000266780 | Japan | A | |
| 2000266780 | Japan | A | |
| 2000205396 | – | – | – |
| 2000266780 | – | – | – |
| JP20000205396 | – | – | – |
| JP20000266780 | – | – | – |
Members69
| Document | Office | Kind | |
|---|---|---|---|
| CA2415558A1 | Canada | A1 | |
| CA2703697A1 | Canada | A1 | |
| WO0204461A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU6791601A | Australia | A | |
| JP2002145883A | Japan | A | |
| NO20030022D0 | Norway | D0 | |
| KR20030014294A | Republic of Korea | A | |
| NO20030022L | Norway | L | |
| EP1298132A1 | European Patent Office (EPO) | A1 | |
| CZ200318A3This record | Czechia | A3 | |
| IL153546A0 | Israel | A0 | |
| IL153546D0 | Israel | D0 | |
| US2003134872A1 | United States of America | A1 | |
| HK1051362A | Hong Kong, China | A | |
| HK1051362A1 | Hong Kong, China | A1 | |
| BR0112168A | Brazil | A | |
| HU0301645A2 | Hungary | A2 | |
| HU1100350A2 | Hungary | A2 | |
| HUP0301645A2 | Hungary | A2 | |
| HUP1100350A2 | Hungary | A2 | |
| MXPA03000031A | Mexico | A | |
| CN1452624A | China | A | |
| US6693115B2 | United States of America | B2 | |
| EP1298132A4 | European Patent Office (EPO) | A4 | |
| ZA200300047B | South Africa | B | |
| PL359393A1 | Poland | A1 | |
| AU2001267916B2 | Australia | B2 | |
| RU2238275C1 | Russian Federation | C1 | |
| NZ523416A | New Zealand | A | |
| CN1214031C | China | C | |
| HU0301645A3 | Hungary | A3 | |
| HUP0301645A3 | Hungary | A3 | |
| EP1298132B1 | European Patent Office (EPO) | B1 | |
| EP1728794A1 | European Patent Office (EPO) | A1 | |
| AT346071T | Austria | T | |
| ATE346071T1 | Austria | T1 | |
| DE60124712D1 | Germany | D1 | |
| PT1298132E | Portugal | E | |
| IL153546A | Israel | A | |
| DK1298132T3 | Denmark | T3 | |
| ES2276801T3 | Spain | T3 | |
| HK1096684A | Hong Kong, China | A | |
| HK1096684A1 | Hong Kong, China | A1 | |
| DE60124712T2 | Germany | T2 | |
| JP4001199B2 | Japan | B2 | |
| TWI290927B | Taiwan Province of China | B | |
| KR20080021152A | Republic of Korea | A | |
| EP1728794B1 | European Patent Office (EPO) | B1 | |
| AT398624T | Austria | T | |
| ATE398624T1 | Austria | T1 | |
| PT1728794E | Portugal | E | |
| DE60134508D1 | Germany | D1 | |
| DK1728794T3 | Denmark | T3 | |
| ES2308633T3 | Spain | T3 | |
| KR20090033917A | Republic of Korea | A | |
| NO328651B1 | Norway | B1 | |
| CY1107554T1 | Cyprus | T1 | |
| CY2009011I1 | Cyprus | I1 | |
| CY2009011I2 | Cyprus | I2 | |
| CA2415558C | Canada | C | |
| KR20100105763A | Republic of Korea | A | |
| PL208386B1 | Poland | B1 | |
| CZ302990B6 | Czechia | B6 | |
| HU227746B1 | Hungary | B1 | |
| KR20120062906A | Republic of Korea | A | |
| CA2703697C | Canada | C | |
| KR20130118395A | Republic of Korea | A | |
| CY1110395T1 | Cyprus | T1 | |
| HU230762B1 | Hungary | B1 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Patent expiredExpiredMK4A | MK4A |
Numbers
- Publication, DOCDB
- 200318
- Publication, EPODOC
- CZ200318
- Application
- 200318
- Application, DOCDB
- 200318
- Application, EPODOC
- CZ20030000018
Titles2
- Czech
- Adiční soli derivátů hydropyridinu s kyselinami, příprava a použití
- English
- Hydropyridine derivative acid addition salts, process of their preparation and use
Classification
- CPC, 3
- C07D495/04
- A61P7/02
- A61P9/10
- IPC, 4
- A61K31 4365
- A61P7 02
- A61P9 10
- C07D495 04